UMB Bank n.a. Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

UMB Bank n.a. decreased its stake in Zoetis Inc. (NYSE:ZTS) by 1.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,146 shares of the company’s stock after selling 950 shares during the period. UMB Bank n.a.’s holdings in Zoetis were worth $14,877,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Global Assets Advisory LLC acquired a new stake in Zoetis during the 1st quarter valued at $8,831,000. Franklin Street Advisors Inc. NC increased its stake in Zoetis by 4.3% during the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock worth $20,478,000 after buying an additional 5,035 shares during the period. Prevail Innovative Wealth Advisors LLC lifted its holdings in Zoetis by 24.5% in the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock worth $3,211,000 after buying an additional 3,738 shares in the last quarter. Finally, Jacobi Capital Management LLC raised its stake in Zoetis by 10.9% during the fourth quarter. Jacobi Capital Management LLC now owns 8,040 shares of the company’s stock valued at $1,587,000 after buying an additional 788 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $0.39 during trading hours on Thursday, hitting $189.78. The stock had a trading volume of 245,789 shares, compared to its average volume of 2,549,461. The stock’s fifty day simple moving average is $187.72 and its 200 day simple moving average is $175.87. The firm has a market capitalization of $86.60 billion, a price-to-earnings ratio of 36.64, a PEG ratio of 2.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $1.41 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ZTS. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.